벤조디아제핀: 약리학의 최신지견 및 현실적 문제

키워드

참고문헌 (269)

1. Winstock AR., "Global drug survey. GDS2019 key findings report:executive summary" (2019), GDS Core Research Team
2. "SSRIs and benzodiazepines for general anxiety disorders (GAD)"[URL]
3. Baenninger A, "Good chemistry : the life and legacy of valium inventor Leo Sternbach" (2004), McGraw Hill Professional
4. Wick JY, "The history of benzodiazepines", Consult Pharm, 28, pp.538~548 (2013)
5. Dell’osso B, "Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal", Eur Psychiatry, 28, pp.7~20 (2013)
6. Ban TA, "In memory of three pioneers", Int J Neuropsychopharmacol, 9, pp.475~477 (2006)
7. Balon R, "Role of benzodiazepines in anxiety disorders", Adv Exp Med Biol, 1191, pp.367~388 (2020)
8. Chouinard G., "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound", J Clin Psychiatry, 65(Suppl 5), pp.7~12 (2004)
9. Nardi AE, "Clonazepam in the treatment of psychiatric disorders : an update", Int Clin Psychopharmacol, 21, pp.131~142 (2006)
10. Griffin CE 3rd, "Benzodiazepine pharmacology and central nervous system-mediated effects", Ochsner J, 13, pp.214~223 (2013)
11. Park WM, "Textbook of clinical neuropsychopharmacology", pp.338~346 (2019), Sigmapress
12. "Drug Classification of Benzodiazepines"[URL]
13. "Benzodiazepines drug class"[URL]
14. Trevor AJ, "Basic & clinical pharmacology" (1995), McGraw Hill
15. "Benzodiazepine: use, abuse and dipendence"[URL]
16. Preskorn SH, "A way of conceptualizing benzodiazepines to guide clinical use", J Psychiatr Pract, 21, pp.436~441 (2015)
17. Schatzberg AF, "Essentials of clinical psychopharmacology", pp.539~569 (2006), American Psychiatric Publishing
18. Alexander SP, "Guide to receptors and channels (GRAC), 5th edition", Br J Pharmacol, 164(Suppl 1), pp.S1~S324 (2011)
19. Nutt DJ, "Making sense of GABA(A)receptor subtypes : is a new nomenclature needed?", J Psychopharmacol, 19, pp.219~220 (2005)
20. Hood SD, "Benzodiazepine dependence and its treatment with low dose flumazenil", Br J Clin Pharmacol, 77, pp.285~294 (2014)
21. Fanselow MS, "The benzodiazepine inverse agonist DMCM as an unconditional stimulus for fear-induced analgesia : implications for the role of GABAA receptors in fear-related behavior", Behav Neurosci, 106, pp.336~344 (1992)
22. Contó MB, "Behavioral differences between subgroups of rats with high and low threshold to clonic convulsions induced by DMCM, a benzodiazepine inverse agonist", Pharmacol Biochem Behav, 82, pp.417~426 (2005)
23. Rudolph U, "Beyond classical benzodiazepines : novel therapeutic potential of GABAA receptor subtypes", Nat Rev Drug Discov, 10, pp.685~697 (2011)
24. Fox C, "Clinical aspects of pain medicine and interventional pain management:a comprehensive review", pp.543~552 (2011), ASIP Publishing
25. Castellano D, "Looking for novelty in an"old"receptor : recent advances toward our understanding of GABAARs and their implications in receptor pharmacology", Front Neurosci, 14, pp.616298~ (2021)
26. de Queiroz AC, "Brain changes in leukemias. Histopathological aspects of choroid plexus involvement", Arq Neuropsiquiatr, 36, pp.332~339 (1978)[DOI]
27. DeLorey TM, "Gamma-aminobutyric acidA receptor structure and function", J Biol Chem, 267, pp.16747~16750 (1992)
28. Olsen RW, "International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update", Pharmacol Rev, 60, pp.243~260 (2008)
29. Nutt DJ, "New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder", Br J Psychiatry, 179, pp.390~396 (2001)
30. Sigel E, "Mapping of the benzodiazepine recognition site on GABA(A)receptors", Curr Top Med Chem, 2, pp.833~839 (2002)
31. Jansen M, "Synthesis of GABAA receptor agonists and evaluation of their alpha-subunit selectivity and orientation in the GABA binding site", J Med Chem, 51, pp.4430~4448 (2008)
32. Sigel E, "The benzodiazepine binding sites of GABAA receptors", Trends Pharmacol Sci, 39, pp.659~671 (2018)
33. Gravielle MC, "Regulation of GABAA receptors by prolonged exposure to endogenous and exogenous ligands", Neurochem Int, 118, pp.96~104 (2018)
34. Möhler H, "A new benzodiazepine pharmacology", J Pharmacol Exp Ther, 300, pp.2~8 (2002)
35. Rowlett JK, "Selective antagonism of GABAA receptor subtypes : an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs", CNS Spectr, 10, pp.40~48 (2005)
36. Atack JR, "The benzodiazepine binding site of GABA(A)receptors as a target for the development of novel anxiolytics", Expert Opin Investig Drugs, 14, pp.601~618 (2005)
37. Dias R, "Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines", J Neurosci, 25, pp.10682~10688 (2005)
38. Basit H, "Clonazepam" (2021), StatPearls Publishing
39. Collinson N, "Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor", J Neurosci, 22, pp.5572~5580 (2002)
40. D’Hulst C, "The complexity of the GABAA receptor shapes unique pharmacological profiles", Drug Discov Today, 14, pp.866~875 (2009)
41. Haddad PM, "Seminars in clinical psychopharmacology", pp.1~34 (2020), Cambridge University Press
42. Mathers DA, "(-)Pentobarbital opens ion channels of long duration in cultured mouse spinal neurons", Science, 209, pp.507~509 (1980)
43. Möhler H, "Benzodiazepine receptor : demonstration in the central nervous system", Science, 198, pp.849~851 (1977)
44. Braestrup C, "Specific benzodiazepine receptors in rat brain characterized by high-affinity(3H)diazepam binding", Proc Natl Acad Sci U S A, 74, pp.3805~3809 (1977)
45. Twyman RE, "Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital", Ann Neurol, 25, pp.213~220 (1989)
46. Lavoie AM, "Direct evidence for diazepam modulation of GABAA receptor microscopic affinity", Neuropharmacology, 35, pp.1383~1392 (1996)
47. Vicini S, "Actions of benzodiazepine and beta-carboline derivatives on gamma-aminobutyric acid-activated Clchannels recorded from membrane patches of neonatal rat cortical neurons in culture", J Pharmacol Exp Ther, 243, pp.1195~1201 (1987)
48. Rogers CJ, "Benzodiazepine and betacarboline regulation of single GABAA receptor channels of mouse spinal neurones in culture", J Physiol, 475, pp.69~82 (1994)
49. Ebert U, "Basic mechanisms of psychotropic drugs", Epilepsia, 43(Suppl 2), pp.2~7 (2002)
50. Bianchi MT, "Agonist trapping by GABAA receptor channels", J Neurosci, 21, pp.9083~9091 (2001)
51. Campo-Soria C, "Mechanism of action of benzodiazepines on GABAA receptors", Br J Pharmacol, 148, pp.984~990 (2006)
52. Lema GM, "Modes and models of GABA(A)receptor gating", J Physiol, 572(Pt 1), pp.183~200 (2006)
53. Gielen MC, "Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding", J Neurosci, 32, pp.5707~5715 (2012)
54. Laverty D, "Crystal structures of a GABAA-receptor chimera reveal new endogenous neurosteroid-binding sites", Nat Struct Mol Biol, 24, pp.977~985 (2017)
55. Sugasawa Y, "Site-specific effects of neurosteroids on GABAA receptor activation and desensitization", Elife, 9, pp.e55331~ (2020)
56. Vinkers CH, "Mechanisms underlying tolerance after longterm benzodiazepine use : a future for subtype-selective GABA(A)receptor modulators?", Adv Pharmacol Sci, 2012, pp.416864~ (2012)
57. Petrache AL, "Selective modulation of α5 GABAA receptors exacerbates aberrant inhibition at key hippocampal neuronal circuits in APP mouse model of Alzheimer’s disease", Front Cell Neurosci, 14, pp.568194~ (2020)
58. Walters RJ, "Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms", Nat Neurosci, 3, pp.1274~1281 (2000)
59. Baur R, "Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs", J Neurochem, 106, pp.2353~2363 (2008)
60. Wongsamitkul N, "α subunits in GABAA receptors are dispensable for GABA and diazepam action", Sci Rep, 7, pp.15498~ (2017)
61. Masiulis S, "GABAA receptor signalling mechanisms revealed by structural pharmacology", Nature, 565, pp.454~459 (2019)
62. Kim JJ, "Shared structural mechanisms of general anaesthetics and benzodiazepines", Nature, 585, pp.303~308 (2020)
63. Lian JJ, "Flumazenil-insensitive benzodiazepine effects in recombinant αβ and neuronal GABAA receptors", Brain Sci, 10, pp.150~ (2020)
64. Schulte C, "Expanding GABAAR pharmacology via receptor-associated proteins", Curr Opin Pharmacol, 57, pp.98~106 (2021)
65. Ge Y, "Clptm1 limits forward trafficking of GABAA receptors to scale inhibitory synaptic strength", Neuron, 97, pp.596~610 (2018)[DOI]
66. Han W, "Shisa7is a GABAA receptor auxiliary subunit controlling benzodiazepine actions", Science, 366, pp.246~250 (2019)
67. Schmitz LJM, "The AMPA receptor-associated protein Shisa7regulates hippocampal synaptic function and contextual memory", Elife, 6, pp.e24192~ (2017)
68. Veenman L, "Channel-like functions of the 18-kDa translocator protein(TSPO) : regulation of apoptosis and steroidogenesis as part of the host-defense response", Curr Pharm Des, 13, pp.2385~2405 (2007)
69. Papadopoulos V, "Peripheraltype benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders", Neuroscience, 138, pp.749~756 (2006)
70. Whirl-Carrillo M, "Pharmacogenomics knowledge for personalized medicine", Clin Pharmacol Ther, 92, pp.414~417 (2012)
71. Gallager DW, "Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity", Nature, 308, pp.74~77 (1984)
72. Uusi-Oukari M, "Regulation of GABA(A)receptor subunit expression by pharmacological agents", Pharmacol Rev, 62, pp.97~135 (2010)
73. Lorenz-Guertin JM, "Diazepam accelerates GABAAR synaptic exchange and alters intracellular trafficking", Front Cell Neurosci, 13, pp.163~ (2019)
74. Leidenheimer NJ, "Acute effects of ethanol on GABAA receptor function : molecular and physiological determinants", Adv Biochem Psychopharmacol, 47, pp.269~279 (1992)
75. Nakamura K, "Phenytoin versus fosphenytoin for second-line treatment of status epilepticus : propensity score matching analysis using a nationwide inpatient database", Seizure, 80, pp.124~130 (2020)
76. Nicholson MW, "Diazepam-induced loss of inhibitory synapses mediated by PLCδ", Ca2+, Mol Psychiatry, pp.2018, 23[DOI]
77. Jacob TC, "Benzodiazepine treatment induces subtype-specific changes in GABA(A)receptor trafficking and decreases synaptic inhibition", Proc Natl Acad Sci U S A, 109, pp.18595~18600 (2012)
78. Poisbeau P, "Silent GABAA synapses during flurazepam withdrawal are region-specific in the hippocampal formation", J Neurosci, 17, pp.3467~3475 (1997)
79. Foitzick MF, "Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor α1 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons", Neurosci Lett, 721, pp.134801~ (2020)
80. Bateson AN, "Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal", Curr Pharm Des, 8, pp.5~21 (2002)
81. Kauer JA, "Synaptic plasticity and addiction", Nat Rev Neurosci, 8, pp.844~858 (2007)
82. Tan KR, "Hooked on benzodiazepines : GABAA receptor subtypes and addiction", Trends Neurosci, 34, pp.188~197 (2011)
83. Chuang SH, "Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain : therapeutic insights for epilepsy", J Pharmacol Exp Ther, 364, pp.180~197 (2018)
84. Gataullina S, "Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy", Dev Med Child Neurol, 61, pp.891~898 (2019)
85. Ben-Ari Y, "GABA : a pioneer transmitter that excites immature neurons and generates primitive oscillations", Physiol Rev, 87, pp.1215~1284 (2007)
86. Kaila K, "GABA actions and ionic plasticity in epilepsy", Curr Opin Neurobiol, 26, pp.34~41 (2014)
87. Macdonald RL, "Mutations in GABAA receptor subunits associated with genetic epilepsies", J Physiol, 588(Pt 11), pp.1861~1869 (2010)
88. Tretter V, "The clustering of GABA(A)receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin", J Neurosci, 28, pp.1356~1365 (2008)
89. 최가영, "Gephyrin: a central GABAergic synapse organizer", Experimental and Molecular Medicine, 47, pp.1~10 (2015), 생화학분자생물학회
90. Dejanovic B, "Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy", EMBO Mol Med, 7, pp.1580~1594 (2015)
91. Lionel AC, "Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures", Hum Mol Genet, 22, pp.2055~2066 (2013)
92. Schipper S, "Tonic GABAA receptors as potential target for the treatment of temporal lobe epilepsy", Mol Neurobiol, 53, pp.5252~5265 (2016)
93. Palma E, "Modulation of GABAA receptors in the treatment of epilepsy", Curr Pharm Des, 23, pp.5563~5568 (2017)
94. Janković SM, "Experimental GABA A receptor agonists and allosteric modulators for the treatment of focal epilepsy", J Exp Pharmacol, 13, pp.235~244 (2021)
95. Verret L, "Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model", Cell, 149, pp.708~721 (2012)
96. Frere S, "Alzheimer’s disease : from firing instability to homeostasis network collapse", Neuron, 97, pp.32~58 (2018)
97. Selkoe DJ, "Early network dysfunction in Alzheimer’s disease", Science, 365, pp.540~541 (2019)
98. Gueli MC, "Alzheimer’s disease : amino acid levels and brain metabolic status", Neurol Sci, 34, pp.1575~1579 (2013)
99. Zimmer R, "Gamma-aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer’s type", Arch Neurol, 41, pp.602~604 (1984)
100. Grouselle D, "Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele", Neurosci Lett, 255, pp.21~24 (1998)
101. Bareggi SR, "Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer’s disease. Age-or disease-related modifications?", Arch Neurol, 39, pp.709~712 (1982)
102. Limon A, "Loss of functional GABA(A)receptors in the Alzheimer diseased brain", Proc Natl Acad Sci U S A, 109, pp.10071~10076 (2012)
103. Li Y, "Implications of GABAergic neurotransmission in Alzheimer’s disease", Front Aging Neurosci, 8, pp.31~ (2016)
104. Drott J, "Etazolate improves performance in a foraging and homing task in aged rats", Eur J Pharmacol, 634, pp.95~100 (2010)
105. Shao H, "Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer’s disease transgenic mice", J Alzheimers Dis, 41, pp.499~513 (2014)
106. Zhang Y, "Chronic treatment with anesthetic propofol attenuates β-amyloid protein levels in brain tissues of aged mice", Transl Neurodegener, 3, pp.8~ (2014)
107. Gabriella G, "γ-Aminobutyric acid type A(GABAA)receptor subtype inverse agonists as therapeutic agents in cognition", Methods Enzymol, 485, pp.197~211 (2010)
108. benzotriazine core acting at γ-aminobutyric acid type A (GABAA)receptor, "Bioorg Med Chem", 2013, 2186~2198
109. Helm KA, "GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element(CRE)in the hippocampus", Neuropharmacology, 48, pp.956~964 (2005)
110. Jo S, "GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease", Nat Med, 20, pp.886~896 (2014)
111. Defazio G, "Descriptive epidemiology of cervical dystonia", Tremor Other Hyperkinet Mov (N Y), 3, pp.tre-03-193-4374-2~ (2013)
112. Jinnah HA, "The focal dystonias : current views and challenges for future research", Mov Disord, 28, pp.926~943 (2013)
113. Jinnah HA, "Diagnosis and treatment of dystonia", Neurol Clin, 33, pp.77~100 (2015)
114. Dresel C, "Multiple changes of functional connectivity between sensorimotor areas in focal hand dystonia", J Neurol Neurosurg Psychiatry, 85, pp.1245~1252 (2014)
115. Berman BD, "GABAA receptor availability changes underlie symptoms in isolated cervical dystonia", Front Neurol, 9, pp.188~ (2018)
116. Groth CL, "Cervical dystonia is associated with aberrant inhibitory signaling within the thalamus", Front Neurol, 11, pp.575879~ (2021)
117. Clarkson AN, "Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke", Nature, 468, pp.305~309 (2010)
118. Wu C, "GABA receptors in brain development, function, and injury", Metab Brain Dis, 30, pp.367~379 (2015)
119. Kim GH, "Low prefrontal GABA levels are associated with poor cognitive functions in professional boxers", Front Hum Neurosci, 13, pp.193~ (2019)
120. Gibson CJ, "Traumatic brain injury and the effects of diazepam, diltiazem, and MK-801 on GABA-A receptor subunit expression in rat hippocampus", J Biomed Sci, 17, pp.38~ (2010)
121. Wassef A, "GABA and schizophrenia : a review of basic science and clinical studies", J Clin Psychopharmacol, 23, pp.601~640 (2003)
122. Mueller TM, "Post-translational protein modifications in schizophrenia", NPJ Schizophr, 6, pp.5~ (2020)
123. Williams SE, "Aberrant glycosylation in schizophrenia : a review of 25 years of post-mortem brain studies", Mol Psychiatry, 25, pp.3198~3207 (2020)
124. Ro154513, "Mol Psychiatry", 2021, 2616~2625
125. Japha K, "Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats : reversal by haloperidol", Psychopharmacology(Berl), 144, pp.347~354 (1999)
126. Tomitaka S, "Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine(MK-801)injures pyramidal neurons in rat retrosplenial cortex", Eur J Neurosci, 12, pp.1420~1430 (2000)
127. Ito K, "The role of gamma-aminobutyric acid(GABA)-benzodiazepine neurotransmission in an animal model of methamphetamineinduced psychosis", Hokkaido Igaku Zasshi, 74, pp.135~144 (1999)
128. Ghosal S, "Prefrontal cortex GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression", Curr Opin Behav Sci, 14, pp.1~8 (2017)
129. Lener MS, "Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine", Biol Psychiatry, 81, pp.886~897 (2017)
130. Godfrey KEM, "Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls : a systematic review and meta-analysis", J Psychiatr Res, 105, pp.33~44 (2018)
131. Fogaça MV, "Cortical GABAergic dysfunction in stress and depression : new insights for therapeutic interventions", Front Cell Neurosci, 13, pp.87~ (2019)
132. Luscher B, "GABAA receptor traffickingmediated plasticity of inhibitory synapses", Neuron, 70, pp.385~409 (2011)
133. Kim YK, "Common and distinct brain networks underlying panic and social anxiety disorders", Prog Neuropsychopharmacol Biol Psychiatry, 80(Pt B), pp.115~122 (2018)
134. Duman RS, "Altered connectivity in depression : GABA and glutamate neurotransmitter deficits and reversal by novel treatments", Neuron, 102, pp.75~90 (2019)
135. Khong TP, "Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States", Calcif Tissue Int, 91, pp.24~31 (2012)
136. Liebrenz M, "High-dose benzodiazepine dependence : a qualitative study of patients’ perception on cessation and withdrawal", BMC Psychiatry, 15, pp.116~ (2015)
137. Liebrenz M, "High-dose benzodiazepine dependence: a qualitative study of patients’ perceptions on initiation, reasons for use, and obtainment", PLoS One, 10, pp.e0142057~ (2015)
138. Liebrenz M, "High-dose benzodiazepine users’ perceptions and experiences of anterograde amnesia", J Am Acad Psychiatry Law, 44, pp.328~337 (2016)
139. Alexander B, "Detoxification from benzodiazepines : schedules and strategies", J Subst Abuse Treat, 8, pp.9~17 (1991)
140. "Zentralbl Chir", 2016, 75~81, German.
141. "Nervenarzt", 1996, 381~386, German.
142. Cloos JM, "Benzodiazepine high-doses : the need for an accurate definition", Int J Methods Psychiatr Res, 30, pp.e1888~ (2021)
143. "Definition and general considerations"[URL]
144. Kan CC, "High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria", Acta Psychiatr Scand, 96, pp.85~93 (1997)
145. Zandstra SM, "Different study criteria affect the prevalence of benzodiazepine use", Soc Psychiatry Psychiatr Epidemiol, 37, pp.139~144 (2002)
146. Kurko TA, "Long-term use of benzodiazepines:definitions, prevalence and usage patterns - a systematic review of register-based studies", Eur Psychiatry, 30, pp.1037~1047 (2015)
147. Nakra BR, "Management of anxiety in the elderly", Compr Ther, 12, pp.53~60 (1986)
148. Teboul E, "A guide to benzodiazepine selection. Part II: clinical aspects", Can J Psychiatry, 36, pp.62~73 (1991)
149. Etchepare F, "Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients", Fundam Clin Pharmacol, 30, pp.82~92 (2016)
150. Willems IA, "Tolerance to benzodiazepines among long-term users in primary care", Fam Pract, 30, pp.404~410 (2013)
151. Logan KE, "Long term use of hypnotics and anxiolytics. May not result in increased tolerance", BMJ, 309, pp.742~743 (1994)
152. Baldwin DS, "Benzodiazepines: risks and benefits. A reconsideration", J Psychopharmacol, 27, pp.967~971 (2013)
153. Hasin DS, "DSM-5 criteria for substance use disorders : recommendations and rationale", Am J Psychiatry, 170, pp.834~851 (2013)
154. Cloos JM, "Hypnotics and triazolobenzodiazepines-best predictors of high-dose benzodiazepine use : results from the Luxembourg National Health Insurance Registry", Psychother Psychosom, 84, pp.273~283 (2015)
155. Martínez-Cano H, "Benzodiazepine types in high versus therapeutic dose dependence", Addiction, 91, pp.1179~1186 (1996)
156. Takeshima N, "Continuation and discontinuation of benzodiazepine prescriptions : a cohort study based on a large claims database in Japan", Psychiatry Res, 237, pp.201~207 (2016)
157. Votaw VR, "The epidemiology of benzodiazepine misuse : a systematic review", Drug Alcohol Depend, 200, pp.95~114 (2019)
158. "Enforcement decree of the narcotics control sct"[URL]
159. Linsen SM, "Defining benzodiazepine dependence : the confusion persists", Eur Psychiatry, 10, pp.306~311 (1995)
160. Lader MH, "Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?", Eur Neuropsychopharmacol, 9(Suppl 6), pp.S399~S405 (1999)[DOI]
161. Woods JH, "Use and abuse of benzodiazepines. Issues relevant to prescribing", JAMA, 260, pp.3476~3480 (1988)
162. Soumerai SB, "Lack of relationship between long-term use of benzodiazepines and escalation to high dosages", Psychiatr Serv, 54, pp.1006~1011 (2003)
163. Lader M, "History of benzodiazepine dependence", J Subst Abuse Treat, 8, pp.53~59 (1991)
164. Lader M, "Benzodiazepines revisited--will we ever learn?", Addiction, 106, pp.2086~2109 (2011)
165. Lader M, "Effectiveness of benzodiazepines : do they work or not?", Expert Rev Neurother, 8, pp.1189~1191 (2008)
166. Tyrer P, "Dependence on benzodiazepines", Br J Psychiatry, 137, pp.576~577 (1980)
167. Ballenger JC, "Long-term pharmacologic treatment of panic disorder", J Clin Psychiatry, 52(Suppl), pp.18~23 (1991)[DOI]
168. Uhlenhuth EH, "International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders", J Clin Psychopharmacol, 19(6 Suppl 2), pp.23S~29S (1999)[DOI]
169. Alessi-Severini S, "Sustained use of benzodiazepines and escalation to high doses in a Canadian population", Psychiatr Serv, 67, pp.1012~1018 (2016)
170. Woods JH, "Abuse liability of benzodiazepines", Pharmacol Rev, 39, pp.251~413 (1987)
171. Woods SW, "Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder", J Clin Psychopharmacol, 12, pp.32~38 (1992)
172. Salzman C, "What are the risks of benzodiazepine dependence?", Harv Ment Health Lett, 16, pp.8~ (1999)
173. Shader RI, "Use of benzodiazepines in anxiety disorders", N Engl J Med, 328, pp.1398~1405 (1993)
174. Ross DC, "Clonazepam for OCD", J Am Acad Child Adolesc Psychiatry, 32, pp.470~471 (1993)
175. O’brien CP, "Benzodiazepine use, abuse, and dependence", J Clin Psychiatry, 66(Suppl 2), pp.28~33 (2005)
176. Marks J, "Benzodiazepines: a 1990 update. Introduction", Hosp Pract (Off Ed), 25(Suppl 2), pp.5~7 (1990)
177. Renner Jr JA, "Massachusetts general hospital psychopharmacology and neurotherapeutics", pp.531~569 (2016), Elsevier
178. Robertson R, "Benzodiazepines : the time for systematic change is now", Addiction, 116, pp.2246~2247 (2021)
179. Shader RI, "Appropriate use and regulatory control of benzodiazepines", J Clin Pharmacol, 31, pp.781~784 (1991)
180. Schwartz HI, "Regulation of benzodiazepine prescribing practices : clinical implications", Gen Hosp Psychiatry, 13, pp.219~224 (1991)
181. Reidenberg MM, "Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State", Clin Pharmacol Ther, 50, pp.129~131 (1991)
182. Hoffman RS, "Has the New York State triplicate benzodiazepine prescription regulation influenced sedative-hypnotic overdoses?", N Y State J Med, 91, pp.436~439 (1991)
183. Salzman C, "Addiction to benzodiazepines", Psychiatr Q, 69, pp.251~261 (1998)
184. Silberman E, "Benzodiazepines : it’s time to return to the evidence", Br J Psychiatry, 218, pp.125~127 (2021)
185. Maust DT, "Benzodiazepine use and misuse among adults in the United States", Psychiatr Serv, 70, pp.97~106 (2019)
186. Tone A, "Listening to the past: history, psychiatry, and anxiety", Can J Psychiatry, 50, pp.373~380 (2005)
187. Salzman C, "Benzodiazepine use and risk for Alzheimer disease", J Clin Psychopharmacol, 35, pp.1~3 (2015)
188. Balon R, "International task force on benzodiazepines", Psychother Psychosom, 87, pp.193~194 (2018)
189. DuPont RL, "Should patients with substance use disorders be prescribed benzodiazepines?", J Addict Med, 11, pp.84~86 (2017)
190. Park TW, "Debate: are benzodiazepines appropriate treatments for patients with substance use disorders? Yes", J Addict Med, 11, pp.87~89 (2017)
191. Saitz R, "Should benzodiazepines be used to treat anxiety in people with substance use disorders? Contentious debate with similar conclusions", J Addict Med, 11, pp.83~ (2017)
192. Serdarevic M., "The truth about benzodiazepines in an age of anxiety:dangers of dogmatic and “propagandist” stances", Psychology Today, ~ (2020)
193. Generalised anxiety disorder and panic disorder in adults: management, "National Institute for Health and Care Excellence", National Institute for Health and Care Excellence, ~ (2019)
194. David S, "Oxford handbook of psychiatry", pp.235~261 (2019), Oxford University Press
195. Taylor DM, "The Maudsley prescribing guidelines in psychiatry", pp.305~450 (2022), Wiley-Blackwell
196. Otto MW, "An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder", Am J Psychiatry, 158, pp.1989~1992 (2001)
197. Kapczinski F, "Antidepressants for generalized anxiety disorder", Cochrane Database Syst Rev, 2, pp.CD003592~ (2003)
198. Zohar J, "Anxiety disorders : a review of tricyclic antidepressants and selective serotonin reuptake inhibitors", Acta Psychiatr Scand Suppl, 403, pp.39~49 (2000)
199. Baldwin D, "Efficacy of drug treatments for generalised anxiety disorder : systematic review and metaanalysis", BMJ, 342, pp.d1199~ (2011)
200. Offidani E, "Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders : a systematic review and meta-analysis", Psychother Psychosom, 82, pp.355~362 (2013)
201. Gomez AF, "Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder : a meta-analytic review", Expert Opin Pharmacother, 19, pp.883~894 (2018)
202. Nardi AE, "Psychopharmacotherapy of panic disorder : 8-week randomized trial with clonazepam and paroxetine", Braz J Med Biol Res, 44, pp.366~373 (2011)
203. Nardi AE, "A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine", J Clin Psychopharmacol, 32, pp.120~126 (2012)
204. Freire RC, "A 6-year posttreatment follow-up of panic disorder patients : treatment with clonazepam predicts lower recurrence than treatment with paroxetine", J Clin Psychopharmacol, 37, pp.429~434 (2017)
205. Benzodiazepine dependence, toxicity, and abuse : a task force report of the American Psychiatric Association, "American Psychiatric Association", American Psychiatric Pub, ~ (1990)
206. Benasi G, "Benzodiazepines as a monotherapy in depressive disorders : a systematic review", Psychother Psychosom, 87, pp.65~74 (2018)
207. Stahl SM, "Selective actions on sleep or anxiety by exploiting GABA-A", benzodiazepine receptor subtypes, 2002, pp.63, 179~180
208. Cosci F, "Clinical methodology matters in epidemiology : not all benzodiazepines are the same", Psychother Psychosom, 84, pp.262~264 (2015)
209. Brandt J, "Benzodiazepines and Z-drugs : an updated review of major adverse outcomes reported on in epidemiologic research", Drugs R D, 17, pp.493~507 (2017)
210. Ehrenstein V, "Clinical epidemiology in the era of big data: new opportunities, familiar challenges", Clin Epidemiol, 9, pp.245~250 (2017)
211. 오탁규, "Benzodiazepine Use and Long-Term Mortality in South Korean Adult Population: A Cohort Study", Yonsei Medical Journal, 62(6), pp.528~534 (2021), 연세대학교의과대학[DOI]
212. Shakir SA, "Causal association in pharmacovigilance and pharmacoepidemiology : thoughts on the application of the Austin Bradford-Hill criteria", Drug Saf, 25, pp.467~471 (2002)
213. Rapoport MJ, "Benzodiazepine use and driving : a meta-analysis", J Clin Psychiatry, 70, pp.663~673 (2009)
214. Cumming RG, "Benzodiazepines and risk of hip fractures in older people : a review of the evidence", CNS Drugs, 17, pp.825~837 (2003)
215. Hill KD, "Psychotropic drug-induced falls in older people : a review of interventions aimed at reducing the problem", Drugs Aging, 29, pp.15~30 (2012)
216. Moore N, "Why are benzodiazepines not yet controlled substances?", JAMA Psychiatry, 72, pp.110~111 (2015)
217. Xing D, "Association between use of benzodiazepines and risk of fractures : a meta-analysis", Osteoporos Int, 25, pp.105~120 (2014)
218. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel, "American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults", J Am Geriatr Soc, 63, pp.2227~2246 (2015)
219. Bentler SE, "The aftermath of hip fracture: discharge placement, functional status change, and mortality", Am J Epidemiol, 170, pp.1290~1299 (2009)
220. Roth T, "Hypnotic use for insomnia management in chronic obstructive pulmonary disease", Sleep Med, 10, pp.19~25 (2009)
221. Stege G, "Sleep, hypnotics and chronic obstructive pulmonary disease", Respir Med, 102, pp.801~814 (2008)
222. Zhang XJ, "The effect of non-benzodiazepine hypnotics on sleep quality and severity in patients with OSA : a meta-analysis", Sleep Breath, 18, pp.781~789 (2014)
223. Mason M, "Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea", Cochrane Database Syst Rev, 7, pp.CD011090~ (2015)
224. Vozoris NT, "Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD", Eur Respir J, 44, pp.332~340 (2014)
225. Ekström MP, "Safety of benzodiazepines and opioids in very severe respiratory disease : national prospective study", BMJ, 348, pp.g445~ (2014)
226. Chung WS, "Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study", Medicine (Baltimore), pp.e1110~ (2015)
227. Nakafero G, "Association between benzodiazepine use and exacerbations and mortality in patients with asthma : a matched case-control and survival analysis using the United Kingdom clinical practice research datalink", Pharmacoepidemiol Drug Saf, 24, pp.793~802 (2015)
228. Barker MJ, "Cognitive effects of long-term benzodiazepine use : a meta-analysis", CNS Drugs, 18, pp.37~48 (2004)
229. Markota M, "Benzodiazepine use in older adults: dangers, management, and alternative therapies", Mayo Clin Proc, 91, pp.1632~1639 (2016)
230. Rummans TA, "Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients", Mayo Clin Proc, 68, pp.731~737 (1993)
231. Egan M, "Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors", J Am Geriatr Soc, 48, pp.811~816 (2000)
232. Neutel CI, "The epidemiology of long-term benzodiazepine use", Int Rev Psychiatry, 17, pp.189~197 (2005)
233. Rikala M, "Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users", Eur J Clin Pharmacol, 67, pp.731~739 (2011)
234. Jang M, "Development of an LC-MS", MS method for the simultaneous determination of 25 benzodiazepines and zolpidem in oral fluid and its application to authentic samples from regular drug users, 2013, pp.74, 213~222
235. Hwang SH, "Trends in the prescription of benzodiazepines for the elderly in Korea", BMC Psychiatry, 17, pp.303~ (2017)
236. Benzodiazepine usage in the North Eastern Health Board region of the Republic of Ireland, "Henman M", Trinity College Dublin, 1~55 (2004)
237. Jacob L, "Long-term use of benzodiazepines in older patients in Germany : a retrospective analysis", Ther Adv Psychopharmacol, 7, pp.191~200 (2017)
238. Zhong G, "Association between benzodiazepine use and dementia : a meta-analysis", PLoS One, 10, pp.e0127836~ (2015)
239. Islam MM, "Benzodiazepine use and risk of dementia in the elderly population : a systematic review and meta-analysis", Neuroepidemiology, 47, pp.181~191 (2016)
240. Espinoza RT, "Clarifying the relationship between benzodiazepines and dementia", J Am Med Dir Assoc, 21, pp.143~145 (2020)
241. Dealberto MJ, "Factors related to current and subsequent psychotropic drug use in an elderly cohort", J Clin Epidemiol, 50, pp.357~364 (1997)
242. Fastbom J, "Benzodiazepines may have protective effects against Alzheimer disease", Alzheimer Dis Assoc Disord, 12, pp.14~17 (1998)
243. Hanlon JT, "Benzodiazepine use and cognitive function among community-dwelling elderly", Clin Pharmacol Ther, 64, pp.684~692 (1998)
244. Boeuf-Cazou O, "Impact of long-term benzodiazepine use on cognitive functioning in young adults : the VISAT cohort", Eur J Clin Pharmacol, 67, pp.1045~1052 (2011)
245. Amieva H, "Prodromal Alzheimer’s disease : successive emergence of the clinical symptoms", Ann Neurol, 64, pp.492~498 (2008)
246. Billioti de Gage S, "Benzodiazepine use and risk of dementia : prospective population based study", BMJ, 345, pp.e6231~ (2012)
247. Billioti de Gage S, "Benzodiazepine use and risk of Alzheimer’s disease : case-control study", BMJ, 349, pp.g5205~ (2014)
248. Gray SL, "Benzodiazepine use and risk of incident dementia or cognitive decline : prospective population based study", BMJ, 352, pp.i90~ (2016)
249. Nader D, "Is long-term benzodiazepine use a risk factor for cognitive decline? Results of a systematic review", J Addict, 2020, pp.1569456~ (2020)
250. Baek Yeon-Hee, "Benzodiazepine-Related Cognitive Impairment or Dementia: A Signal Detection Study Using a Case", Non-Case Approach, 2020, pp.17(6), 587~595[DOI]
251. Brambilla G, "Genotoxicity and carcinogenicity studies of benzodiazepines", Pharmacol Res, 56, pp.443~458 (2007)
252. Kao CH, "Benzodiazepine use possibly increases cancer risk : a populationbased retrospective cohort study in Taiwan", J Clin Psychiatry, 73, pp.e555~e560 (2012)[DOI]
253. Kripke DF, "Hypnotics’ association with mortality or cancer : a matched cohort study", BMJ Open, 2, pp.e000850~ (2012)
254. Iqbal U, "Is long-term use of benzodiazepine a risk for cancer?", Medicine(Baltimore), 94, pp.e483~ (2015)
255. Kim HB, "Use of benzodiazepine and risk of cancer : a meta-analysis of observational studies", Int J Cancer, 140, pp.513~525 (2017)
256. Harnod T, "An association between benzodiazepine use and occurrence of benign brain tumors", J Neurol Sci, 336, pp.8~12 (2014)
257. Xu W, "Use of antidepressants and risk of colorectal cancer : a nested case-control study", Lancet Oncol, 7, pp.301~308 (2006)
258. Fang HF, "Risk of cancer in patients with insomnia, parasomnia, and obstructive sleep apnea:a nationwide nested case-control study", J Cancer, 6, pp.1140~1147 (2015)
259. Chen JC, "Sleep apnea increased incidence of primary central nervous system cancers : a nationwide cohort study", Sleep Med, 15, pp.749~754 (2014)
260. Tsai ML, "The effect of benzodiazepine and nonbenzodiazepine prescriptions for diabetes mellitus type 2 in elderly Taiwanese with depressive symptoms", Psychogeriatrics, 16, pp.93~101 (2016)
261. Weich S, "Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards : retrospective cohort study", BMJ, 348, pp.g1996~ (2014)
262. Kripke DF, "Mortality hazard associated with prescription hypnotics", Biol Psychiatry, 43, pp.687~693 (1998)
263. Tiihonen J, "Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia", Arch Gen Psychiatry, 69, pp.476~483 (2012)
264. Belleville G, "Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey", Can J Psychiatry, 55, pp.558~567 (2010)
265. Mallon L, "Is usage of hypnotics associated with mortality?", Sleep Med, 10, pp.279~286 (2009)
266. Hirschtritt ME, "Balancing the risks and benefits of benzodiazepines", JAMA, 325, pp.347~348 (2021)
267. Penninx BW, "Anxiety disorders", Lancet, 397, pp.914~927 (2021)
268. Tibrewal P, "Benzodiazepines for the long-term treatment of anxiety disorders?", Lancet, 398, pp.119~120 (2021)
269. Horowitz MA, "Risks and benefits of benzodiazepines", JAMA, 325, pp.2208~ (2021)

관련 논문AI추천